Cullinan Therapeutics, Inc. (CGEM)

In the past six months, Cullinan Therapeutics, Inc. (CGEM) stock has increased by 36.34%. Key events include a 16% stock surge in December 2025 following positive clinical data for CLN-049, FDA Fast Track Designation for CLN-049 in December 2025, a corporate update in November 2025 highlighting anticipated 2026 milestones, insider selling by Jennifer Michaelson in December 2025, and a 68% jump in Q2 R&D expenses in August 2025.

Information regarding specific demand seasonality for Cullinan Therapeutics, Inc.'s products and services is not readily available. Demand for its pipeline products is primarily driven by clinical trial progress, regulatory approvals, and eventual market adoption rather than traditional seasonal consumer patterns.

Cullinan Therapeutics, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and autoimmune diseases in the United States. The company operates in the Biotechnology industry and has a diversified pipeline of product candidates, including CLN-619, CLN-049, CLN-418, Zipalertinib (CLN-081/TAS6417), CLN-617, and CLN-978. The company also has a license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies.

Cullinan Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States, with a primary focus on developing therapies within the United States.

Cullinan Therapeutics maintains a generally positive brand reputation, reflected by a consensus "Moderate Buy" rating from analysts and a significant upside potential of approximately 167.6% from its current price. The company's MarketRank™ score indicates it performs better than 67% of companies in the medical sector. Positive events include positive clinical data for CLN-049 in AML, receiving FDA Fast Track Designation for CLN-049, and meeting the primary endpoint in a Phase 2b trial of Zipalertinib.

Cullinan Therapeutics, Inc. has significant institutional ownership, with 284 institutional owners holding 66,001,887 shares, representing 103.39% of the company. Insiders own 82.82%. Ansbert Gadicke is the largest individual shareholder, owning 16.16 million shares (27.35%). Other major holders include MPM Oncology Impact Management LP, Lynx1 Capital Management LP, Bvf Inc/il, BlackRock, Inc., Vanguard Group Inc, Deerfield Management Company, L.p. (series C), Blue Owl Capital Holdings LP, Kynam Capital Management, LP, Citadel Advisors Llc, and Orbimed Advisors Llc.